1. At a Glance
Jagsonpal Pharma just dropped a Q1 mic: revenue up 23% YoY to ₹756 Mn, PAT doubled to ₹108 Mn, and cash reserves at ₹1,609 Mn. The stock’s up 4% because investors finally stopped napping. The CFO resigned right after, probably because even he couldn’t believe these margins.
2. Introduction with Hook
Imagine a startup that sells hope in blister packs but without the drama of an IPO. Jagsonpal is that auntie who’s been around since 1978, still rocking it at weddings while the young ones gasp. Two fun facts:
- Revenue grew 23% in Q1 FY26.
- PAT didn’t just grow—it doubled. Yes, pharma profits now beat your FD returns by a mile.
3. Business Model (WTF Do They Even Do?)
Jagsonpal basically makes medicines for women’s health, bones that crack, and other “please fix me” problems.
- Gynaecology & Orthopaedics = cash cows.
- Other plays: antibiotics, allergy, immunity, OTC, dermatology, pediatrics.
- They have 17 brands in Top 5 molecules—basically the overachievers of pharma.
Punchline: “They sell pills that fix people and pad wallets—like an ethical drug dealer.”
4. Financials Overview
Q1 FY26 Snapshot:
